Vol 14 (2023): Continuous Publishing
Case report
Published online: 2023-06-15

open access

Page views 1598
Article views/downloads 578
Get Citation

Connect on Social Media

Connect on Social Media

Pulmonary embolism after anti-SARS-CoV-2 vaccines in two female patients

Katarzyna Korzeniowska1, Artur Cieślewicz1, Katarzyna Grabańska-Martyńska2, Anna Flotyńska1, Anna Jabłecka1
Hematol Clin Pract 2023;14:18-23.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a coronavirus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. To protect people from severe COVID-19 course, vaccines have been recently developed. Vaccines’ safety was confirmed during clinical trials; however, massive vaccination action resulted in rare cases of adverse effects emerging, such as thromboses associated with thrombocytopenia. We present two cases of pulmonary embolism after anti-SARS-CoV-2 vaccines in two female patients, with negative history of SARS-CoV-2 infections. In both patients additional risk factors for thrombotic events (hormonal contraception, varicose veins) were present. Pulmonary embolism occurs when a blood vessel in the lungs becomes blocked by a blood clot. It is a very rare adverse effect associated with COVID-19 vaccines and is often accompanied by thrombocytopenia. However, recent studies have found that he incidence of pulmonary embolism after COVID-19 vaccines was not increased compared to the general population. Moreover, the risk of PE after vaccination is significantly lower than the incidence of thrombotic events during COVID-19.

Article available in PDF format

View PDF Download PDF file

References

  1. Bellotti Azevedo R, Gopp Botelho B, Gonçalves de Hollanda JV, et al. COVID-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021; 35(1): 4–11.
  2. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145–147.
  3. Bikdeli B, Madhavan MV, Jimenez D, et al. Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75(23): 2950–2973.
  4. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7): 834–847.
  5. COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines (March 20, 2022).
  6. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). https://www.who.int/publications/i/item/9789240061989 (April 20, 2023).
  7. VAXZEVRIA/COVID-19 Vaccine AstraZeneca: risk of thrombosis in combination with thrombocytopenia — updated information. https://www.ema.europa.eu/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria/covid-19-vaccine-astrazeneca-risk-thrombosis-combination-thrombocytopenia-updated-information_en.pdf (March 20, 2022).
  8. COVID-19 Vaccine Janssen: risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE). https://www.ema.europa.eu/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-vaccine-janssen-risk-immune_en.pdf (March 20, 2022).
  9. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005; 172(8): 1041–1046.
  10. Doherty S. Pulmonary embolism An update. Aust Fam Physician. 2017; 46(11): 816–820.
  11. Essien EO, Rali P, Mathai SC. Pulmonary embolism. Med Clin North Am. 2019; 103(3): 549–564.
  12. Kline JA. Diagnosis and exclusion of pulmonary embolism. Thromb Res. 2018; 163: 207–220.
  13. EudraVigilance — European database of suspected adverse drug reaction reports. https://www.adrreports.eu/en/search_subst.html# (March 20, 2022).
  14. European Centre for Disease Prevention and Control. COVID-19 vaccine tracker. https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#distribution-tab (March 30, 2022).
  15. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384(22): 2092–2101.
  16. Jafri A, Prieto A, Gashau H, et al. Thrombotic thrombocytopenia following ChAdOx1 nCov-19 vaccination. Acute Med. 2021; 20(3): 223–226.
  17. Bikdeli B, Jiménez D, Demelo-Rodriguez P, et al. Venous thrombosis within 30 days after vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses. 2022; 14(2).
  18. Waqar U, Ahmed S, Gardezi SM, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: a systematic review. Clin Appl Thromb Hemost. 2021; 27: 10760296211068487.
  19. Konstantinides SV. Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us — and what they don't. Eur Respir J. 2021; 58(1).
  20. Kriegshäuser G, Braunsteiner A. Temporal association between Hampton's hump pulmonary embolism and first-dose ChAdOx1 nCov-19 vaccine in a patient with activated protein C resistance. Vaccines (Basel). 2022; 10(10).
  21. Brazete C, Aguiar A, Furtado I, et al. Thrombotic events and COVID-19 vaccines. Int J Tuberc Lung Dis. 2021; 25(9): 701–707.
  22. Ifeanyi N, Chinenye N, Oladiran O, et al. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021; 11(6): 877–879.
  23. Chan WN, Chen CS, Ho DR, et al. Pulmonary embolism after Moderna vaccination in kidney transplant patients: two case reports and literature review. Vaccines (Basel). 2022; 10(6).
  24. Borisoff BD, Bohn KD, Sager J, et al. Unprovoked submassive saddle pulmonary embolism in an adult male after Pfizer COVID-19 vaccination. Cureus. 2022; 14(8): e27717.
  25. Ogunkoya JO, Ogunmola MI, Ogunlade AF, et al. COVID-19 vaccination associated bilateral pulmonary embolism: cause or coincidence. Case Rep Pulmonol. 2022; 2022: 9596285.
  26. Ahn EY, Choi H, Sim YSu, et al. Pulmonary embolism and inferior vena cava thrombosis pin a young male atient after mRNA-1273 (Moderna) immunization: a case report. Tuberc Respir Dis (Seoul). 2022; 85(4): 361–363.
  27. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021; 372: n699.
  28. Vaxveria. Summary of product characteristics. https://www.ema.europa.eu/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (March 20, 2022).
  29. Østergaard SD, Schmidt M, Horváth-Puhó E, et al. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021; 397(10283): 1441–1443.
  30. Botton J, Jabagi MJ, Bertrand M, et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA. 2022; 327(1): 80–82.
  31. Gong X, Yuan B, Yuan Y. Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis. PLoS One. 2022; 17(3): e0263580.
  32. James AH. Pregnancy, contraception and venous thromboembolism (deep vein thrombosis and pulmonary embolism). Vasc Med. 2017; 22(2): 166–169.
  33. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353: i2002.
  34. Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019; 98(12): 1549–1557.
  35. Mäkivaara LA, Ahti TM, Luukkaala T, et al. Persons with varicose veins have a high subsequent incidence of arterial disease: a population-based study in Tampere, Finland. Angiology. 2007; 58(6): 704–709.
  36. Müller-Bühl U, Leutgeb R, Engeser P, et al. Varicose veins are a risk factor for deep venous thrombosis in general practice patients. Vasa. 2012; 41(5): 360–365.
  37. Chang SL, Huang YL, Lee MC, et al. Association of varicose veins with incident venous thromboembolism and peripheral artery disease. JAMA. 2018; 319(8): 807–817.
  38. Oesch A. Thrombosis and pulmonary embolism risk in patients undergoing varicose vein surgery. Phlebolymphology. 2013; 20(2): 96–100.